Reggie is responsible for the direction, and execution of Lantern’s clinical development plans, and involved in the strategy of the development of the portfolio of programs.
As Vice President of Clinical Development, Reggie is responsible for the direction, and execution of Lantern’s clinical development plans, andinvolved in the strategy of the development of the portfolio of programs.
Prior to joining Lantern in 2023, Reggie had spent over 20 years involved in extensivepreclinical, early phase and late phase drug development research activities includingas a clinical research Faculty at The Ohio State University, and atAstrazeneca, Genzyme, Sanofi, Pfizer, Tesaro/GlaxoSmithkline and Kymera. Reggie served as a senior medical director and global medicallead for development of several drugs while at Pfizer that led to successfulfilings for TrazimeraTM (trastuzumab-qyyp),NyvepriaTM (pegfilgrastim-apgf) andZirabevTM (bevacizumab-bvzr). Inaddition, Reggie also held various leadership roles in Experimental Medicinein Astrazeneca, and in clinical development in Genzyme, Tesaro/GSK and Kymera during which time he ledvarious aspects of both the medical and clinical pharmacology evaluation of severaloncology and non-oncology drugs that informed the use of approved drugs such asCediranib (AZD2171, RecentinTM), Clolar® (clofarabine), Mozobil(plerixafor), Zejula (niraparib) and Jemperli(dostarlimab-gxly).
Reggie received his MBBS degree (MD equivalent)from University of Ibadan, Nigeria, M.Sc. in Clinical Pharmacology from AhmaduBello University, Nigeria, and MBA from Greehey School of Business at St Mary’sUniversity. He has authored more than 20 peer-reviewedpapers published in top-tier medical and scientific journals and chapters inOncology textbooks. He trained in the subspecialtiesof Hematology & Pediatric Oncology, and Clinical Pharmacology &Pharmacogenomics at the University of Chicago. He is Board certified inPediatric Hematology/Oncology and Clinical Pharmacology.